...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Alimentary pharmacology & therapeutics. >Treatment access is only the first step to hepatitis C elimination: experience of universal anti‐viral treatment access in Australia
【24h】

Treatment access is only the first step to hepatitis C elimination: experience of universal anti‐viral treatment access in Australia

机译：治疗访问只是乙型肝炎消除的第一步：澳大利亚的普遍防病毒治疗机会的经验

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Summary Background Global targets to eliminate hepatitis C ( HCV ) might be met by sustained treatment uptake. Aim To describe factors facilitating HCV treatment uptake and potential challenges to sustaining treatment levels after universal access to direct‐acting anti‐virals ( DAA ) across Australia. Methods We analysed national Pharmaceutical Benefits Scheme data to determine the number of DAA prescriptions commenced before and after universal access from March 2016 to June 2017. We inferred facilitators and barriers to treatment uptake, and challenges that will prevent local and global jurisdictions reaching elimination targets. Results In 2016, 32 877 individuals (14% of people living with HCV in Australia) commenced HCV DAA treatment, and 34?952 (15%) individuals commenced treatment in the first year of universal access. Treatment uptake peaked at 13?109 DAA commencements per quarter immediately after universal access, but more than halved (to 5320 in 2017 Q2) within 12?months. General practitioners have written 24% of all prescriptions but with a significantly increased proportion over time (9% in 2016 Q1 to 37% in 2017 Q2). In contrast, hepatology or infectious diseases specialists have written a declining share from 74% to 38% during the same period. General practitioners provided a greater proportion (47%) of care in regional/remote areas than major cities. Conclusions Broad treatment access led to rapid initial increases in treatment uptake, but this uptake has not been sustained. Our results suggest achieving global elimination targets requires more than treatment availability: people with HCV need easy access to testing and linkage to care in community settings employing a diverse prescriber base.
机译：摘要背景技术可能通过持续治疗摄取来满足消除丙型肝炎（HCV）的全局目标。旨在描述促进HCV治疗的因素，并在澳大利亚普遍获得直接作用抗病毒（DAA）后维持治疗水平的潜在挑战。方法分析了国家制药福利计划数据，以确定2016年3月至2017年6月在普遍获取之前和之后开始的DAA处方数目。我们推断出促进者和障碍，以防止当地和全球司法管辖区达成消除目标的挑战。结果2016年，32个877人（澳大利亚居住的人民的14％）开始了HCV Daa治疗，34岁？952（15％）个人在普遍获得的第一年开始治疗。治疗摄取在普遍接入后的每季度达到13°？109 Daa开始，但在12岁以下的时间内（2017年第2季度的5320次）一般从业者编写了所有处方的24％，但随着时间的推移明显增加（2016年的9％Q1至37％）。相比之下，肝脏学或传染病专家在同一时期内书面下降了74％至38％。一般从业者在区域/偏远地区提供比主要城市更大的比例（47％）。结论广泛的处理进入导致治疗摄取的快速初始增加，但这种摄取尚未得到持续。我们的结果表明，实现全球消除目标需要超过治疗可用性：HCV的人们需要轻松访问采用各种前所欲基地的社区设置进行测试和联系。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号